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Abstract
Mucosal mononuclear (MMC) CCR5+CD4+ T cells of the gastrointestinal (GI) tract are selectively infected and depleted
during acute HIV-1 infection. Despite early initiation of combination antiretroviral therapy (cART), gut-associated lymphoid
tissue (GALT) CD4+ T cell depletion and activation persist in the majority of HIV-1 positive individuals studied. This may
result from ongoing HIV-1 replication and T-cell activation despite effective cART. We hypothesized that ongoing viral
replication in the GI tract during cART would result in measurable viral evolution, with divergent populations emerging over
time. Subjects treated during early HIV-1 infection underwent phlebotomy and flexible sigmoidoscopy with biopsies prior
to and 15–24 months post initiation of cART. At the 2
nd biopsy, three GALT phenotypes were noted, characterized by high,
intermediate and low levels of immune activation. A representative case from each phenotype was analyzed. Each subject
had plasma HIV-1 RNA levels ,50 copies/ml at 2
nd GI biopsy and CD4+ T cell reconstitution in the peripheral blood. Single
genome amplification of full-length HIV-1 envelope was performed for each subject pre- and post-initiation of cART in GALT
and PBMC. A total of 280 confirmed single genome sequences (SGS) were analyzed for experimental cases. For each subject,
maximum likelihood phylogenetic trees derived from molecular sequence data showed no evidence of evolved forms in the
GALT over the study period. During treatment, HIV-1 envelope diversity in GALT-derived SGS did not increase and post-
treatment GALT-derived SGS showed no substantial genetic divergence from pre-treatment sequences within transmitted
groups. Similar results were obtained from PBMC-derived SGS. Our results reveal that initiation of cART during acute/early
HIV-1 infection can result in the interruption of measurable viral evolution in the GALT, suggesting the absence of de-novo
rounds of HIV-1 replication in this compartment during suppressive cART.
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Introduction
Acute infection with human immunodeficiency virus type 1
(HIV-1) is a critical time during which host factors including
innate and adaptive immunity converge with virologic character-
istics to determine the course of clinical progression in infected
individuals [1–3]. In the absence of combination antiretroviral
therapy (cART), HIV-1 infection is maintained in a chronic state-
characterized by high levels of viral production with associated
immune activation that is responsible in large part for progressive
CD4+ T cell depletion [4]. Repeated rounds of infection of
susceptible CD4+ cells of various types occur with continued
generation of long-lived cells harboring replication competent
virus, and that persist during therapy [5].
The HIV-1 treatment landscape was transformed when in 1996,
highly active antiretroviral therapy (HAART) became the
standard of care for the treatment of HIV-1 infection. The advent
of HAART is directly credited with the retardation of the overall
progression of HIV infection to AIDS as well as the progression of
AIDS to death. The end result has been a considerable decrease in
morbidity, and increase in survival after AIDS diagnosis [6,7].
Combination antiretroviral drug therapy (cART) can dramatically
suppress HIV replication and reduce the plasma HIV-1 viral load
in compliant patients, resulting in immune reconstitution of
memory CD4+ and CD8+ T cells and the restoration of T cell
immunity [8–11]. Despite these advances, current regimens
remain unable to eliminate the reservoir of latent virus in resting
CD4+ T lymphocytes. As a result, cessation of therapy predictably
results in the resurgence of virus replication [12–17].
The gut-associated lymphoid tissue (GALT) contains the vast
majority, and most complex pool of immune cells [18]. In
addition, intrinsic characteristics of the mucosal compartment,
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gastrointestinal (GI) mucosal CD4+ T cells with a memory
phenotype [19,20] permit HIV-1 infection and accommodate its
replication.
Several studies have examined the critical role played by the GI
tract in early simian immunodeficiency (SIV) pathogenesis. In the
SIV/macaque model, SIV challenge has been shown to result in
early, profound depletion of GI mucosal CD4+ lymphocytes [21–
23]. Additional studies in the SIV/macaque model revealed that
up to 60% of memory CD4+CCR5+ T cells may be selectively
infected and lost during this early stage of infection [24].
We and others have shown that the human GI lymphoid system
is similarly targeted during acute and early HIV-1 infection. A
greater percentage of mucosal CD4+ lymphocytes express the
CCR5 chemokine coreceptor [25–28] when compared to the
peripheral blood. Preferential targeting of the CCR5+ memory
CD4+ T cell subset therefore results in substantial depletion of
CD4+ T cells in the gut-associated lymphoid tissue (GALT). As a
consequence, up to 60% of CD4+ T cells in the lamina propria of
the lower gastrointestinal (GI) tract are lost as early as 2–4 wk after
infection [29–31]. Cross-sectional analysis of a cohort of primary
HIV-1 infection subjects demonstrated that despite immune
reconstitution in the peripheral blood mononuclear cells (PBMCs),
persistent CD4+ T cell depletion and immune activation have
been noted in the GALT in a majority of patients despite up to 5
years of suppressive cART [32,33].
The latent reservoir of HIV-1 is established early in infection
and persists despite the initiation of cART during the primary
phase of infection [12,13,34]. Employing a real-time reverse
transcriptase-initiated PCR single copy assay (SCA), Palmer et al.
have demonstrated that the majority of infected individuals on
‘‘suppressive’’ ART (defined by plasma HIV-1 RNA levels ,50
copies/mL) have persistent HIV-1 viremia below the current limit
of detection of commercially available, and currently less sensitive
assays. This real-time RT-initiated PCR assay quantifies HIV-1
RNA concentration down to 1 copy/mL of plasma with use of an
internal control for viral pelleting and extraction followed by
separate RT-PCR reactions for HIV-1 and virion control
sequences [35].
Numerous studies have attempted to determine if measurable
low-level residual viremia during ‘‘suppressive’’ cART is the result
of ongoing cycles of HIV-1 replication. Studies have suggested that
ongoing viral replication in patients on apparently suppressive
cART may occur [36–46]. These include reports of decreases in
low-level viremia with HAART intensification, persistent expres-
sion of unspliced (US) HIV-1 mRNA in PBMC, persistence of
HIV-1 episomal cDNA in PBMC and modest evolution of viral
envelope sequences over time [36,37,39,40]. Conversely and
generally more recently, others have found no evidence of ongoing
HIV-1 replication during suppressive cART [47–53]. These
include studies that have generated phylogenetic data suggesting
the absence of viral evolution in patients undergoing successful
cART and support the notion that the reservoir is intrinsically
stable [51–53]. Bailey et al. investigated plasma and cellular viral
sequences obtained during suppressive cART and found that in
some patients on antiretroviral therapy, the prolonged production
of a small number of viral clones without evident evolution is a
major mechanism for persistent viremia [47]. Most recently, in-
vitro work by Sigal et al. proposes the possibility of cell to cell
transmission as a mechanism of ongoing HIV-1 replication despite
ART [54]. As a result, the important question of whether or not
there is ongoing HIV-1 replication despite ‘‘suppressive’’ cART
remains under debate.
We hypothesized that one cause of persistent immune activation
and CD4+ T cell depletion in the gastrointestinal lymphoid
compartment despite immune reconstitution in the blood may be
ongoing local HIV-1 replication in the GALT during apparently
suppressive cART, which could potentially constitute a source for
replenishment of the latently infected resting CD4+ T cell pool.
We therefore endeavored to measure qualitatively and quanti-
tatively the degree of HIV-1 evolution in the PBMC and GALT
during cART to determine whether the lymphoid tissue of the GI
tract is a reservoir of ongoing viral replication during suppressive
cART. We hypothesized that ongoing viral replication in the
GALT during suppressive cART would result in measurable viral
evolution, with more divergent populations emerging in the
GALT than in the PBMC over time. We also hypothesized that if
continued HIV-1 replication in the GALT was responsible for the
persistent immune activation in this compartment, the amount of
HIV-1 env evolution would correlate positively with experimentally
determined levels of immune activation, while correlating
negatively with levels of immune reconstitution in the GALT.
This research utilizes the single genome amplification (SGA)
technique to generate HIV-1 variant sequences. This terminal
dilution technique uses a single molecule of DNA or cDNA as the
template for amplification and sequencing [55–58]. SGA has the
ability to achieve a degree of detection of diversity greater than
20% within a repeatedly sampled viral population [59] and has
been shown to decrease taq-induced recombination, template
resampling, nucleotide misincorporation and cloning bias when
compared to more conventional sequencing methods [55–57,60–
62]. The use of this method therefore produces a more accurate
representation of in-vivo HIV-1 quasispecies than compared to
bulk sequencing methods [63].
The mucosal tissues harbor the primary targets of HIV-1
infection and serve as an important route for HIV-1 entry and
replication. For these reasons, understanding the spectrum of
HIV-1 quasispecies in the GI mucosa may be critical in revealing
determinants of viral entry, persistence and developing treatment
strategies to improve viral suppression and overcome an
established obstacle to eradicate HIV-1 in the infected host.
Author Summary
This study was undertaken to determine if the gastroin-
testinal tract is a site of ongoing viral replication during
suppressive combination antiretroviral therapy (cART)
(defined by plasma HIV-1 RNA levels below 50 copies/
ml). We found no evidence of substantial viral evolution in
HIV-1 envelope sequences derived from peripheral blood
mononuclear cells or cells of the gastrointestinal tract
lymphoid tissue in participants initiating cART during early
HIV-1 infection. To our knowledge, this is the first
application of the single genome amplification technique
to the comparative analysis of HIV-1 quasi-species derived
from the gastrointestinal tract, demonstrating that in these
individuals, cART has the ability to halt measurable
evolution of HIV-1 envelope in this compartment. These
findings suggest the absence of de-novo rounds of HIV-1
replication during suppressive cART and by extension, that
experimentally observed, persistently elevated levels of
immune activation in the gastrointestinal lymphoid tissue
seen after the early initiation and uninterrupted use of
cART (despite relative immune reconstitution in the blood)
is likely due to factors other than ongoing viral replication.
This implies that in this virally suppressed population, cART
intensification is unlikely to significantly impact persistent
CD4+ T cell depletion or increased levels of immune
activation in the gastrointestinal tract.
Absence of HIV-1 Evolution in the Gut
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Immunologic and virologic characteristics of the study
groups
In the experimental group, contemporaneous peripheral-blood
and recto-sigmoid colonic mucosal tissue samples were obtained
from three cART-naı ¨ve, HIV-1 seropositive males identified
during acute/early HIV-1 infection (Table 1). Combination
ART was initiated in this group within 72 hrs of flexible
sigmoidoscopy. Experimental subjects reported .95% uninter-
rupted adherence to cART at the time of repeat phlebotomy and
flexible sigmoidoscopy with biopsies 15 to 25 months post
initiation of cART (Table 1). Levels of immune activation and
immune reconstitution following cART for these individuals had
been previously determined at the time of initial sample collection
using flow cytometry and immunohistochemistry respectively.
During early HIV-1 infection, all individuals demonstrated
CD4+ T cell depletion at similar levels in the PBMCs, with CD4/
CD8 ratios below 1 (Figure 1A, 1B). The CD4/CD8 ratio
inversion was more pronounced in the MMC compartment than
in the PBMC compartment for all individuals at this early time
point. Following 1–2 years of cART, all individuals had successful
reconstitution of the peripheral CD4+ T cell compartment, with
substantial increases in peripheral CD4+ T cell counts (Table 1)
and normalization of the CD4/CD8 ratio. Less successful CD4+ T
cell reconstitution in the MMCs was seen, and none of the
individuals reconstituted to a CD4/CD8 ratio .1 despite cART
(Figure 1B). Immunohistochemistry on GI biopsy specimens
further demonstrated the inability of these individuals to fully
reconstitute CD4+ T cells of the GI tract through specific
examination of the lamina propria (LP), an important immune-
effector site where preferential CD4+ T cell depletion occurs
during primary HIV infection [30]. Mean CD4+ T cells per unit
area were severely depressed during early infection. Following 1–2
years of cART, each individual was able to reconstitute LP CD4+
T cells with varying degrees of success, although none quite to the
11.0+/23.3 cells/unit area seen by Mehandru et al. in HIV-1
negative individuals [32](Figure 1D, 1E). Similarly, during
primary HIV-1 infection prior to initiation of cART, levels of
immune activation (as measured by %CD8+CD45RO+HLA-
DR+ T cells) were abnormally elevated in the CD8+ PBMCs and
MMCs for all subjects (Figure 1C). After .1 year on cART, levels
of immune activation in the PBMC compartment dropped
dramatically to levels that approximate those seen in HIV-1
negative individuals (4.8%+/23.9%) [32]. However, in the MMC
compartment, while decreased from primary infection, levels of
memory CD8+ T cell immune activation remained elevated above
that seen in historic HIV-1 negative control individuals (19.8%+/
29.8%) [32], for our High Immune Activator (HIA) at 35.5%.
GALT immune activation levels for the Intermediate Immune
Activator (IIA) and Low Immune Activator (LIA) were 25.2% and
12.1% respectively (Figure 1C).
Given the importance of the GI LP as a target for CD4+ T cell
depletion during primary HIV-1 infection, the link between
persistent immune activation in the CD8+ T cell compartment to
adverse HIV-1 disease progression [64] and the negative
correlation in these three individuals between the ability to
reconstitute CD4+ T cells in the GALT and the degree of residual
CD8+ T cell activation in the MMCs, subjects were chosen based
on the exhibition of one of three phenotypes in the GI lymphoid
tissue at the time of 2
nd biopsy: (1) High Immune Activation (HIA)
with 35.5% CD8+ CD45RO+HLA-DR+ T cells in the mucosal
mononuclear cell (MMC) compartment and an absolute CD4+ T
cell count of 4.3 cells/unit area in the GI lamina propria (2)
Intermediate Immune Activation (IIA) with 25.2%
CD8+CD45RO+HLA-DR+ T cells and an absolute CD4+ T
cell count of 6.7 cells/unit area and (3) Low Immune Activation
(LIA) with 12.1% CD8+CD45RO+HLA-DR+ T cells and an
absolute CD4+ T cell count of 7.2 cells/unit area (Figure 1C, 1E).
All three had plasma HIV-1 viral loads of ,50 copies/ml at the
time of the 2
nd GI biopsy and CD4+ T cell counts of 774, 903 and
556 cells/ml respectively (Table 1). Repeat testing of stored plasma
Table 1. Clinical profile and ARV treatment history for study participants and positive controls.
Participant HIA IIA LIA POS1 POS2
Elisa at Time Point #1 (TP1) + + +++
Western Blot TP1 + + +++
PBMC TP1 12/9/2004 5/5/2004 11/9/2004 3/8/2007 8/10/2006
GALT TP1 12/13/2004 5/6/2004 11/9/2004 N/A N/A
Estimated Duration of Infection PBMC TP1 68 days 30 days 88 days 78 days 54 days
Fiebig Stage TP1 VI V VI V V
CD4 Count cells/ul TP1 442 250 489 656 560
Plasma HIV-1 RNA (VL) copies/ml TP1 148,000 5,560,000 86,100 46,700 72,300
cART Start Date 12/16/2004 5/6/2004 11/16/2004 N/A N/A
Initial cART regimen TDF/FTC+EFV TDF/FTC+LPV/r TDF/FTC+EFV N/A N/A
Time to 1st VL ,50 copies/ml 110 days 113 days 119 days N/A N/A
Time to PBMC TP2 1.3 y (489 d) 1.1 y (414 d) 1.4 y (506 d) 1.9 y (691 d) 1.8 y (670 d)
Time to GALT TP2 1.3 y (489 d) 2.1 y (761 d) 1.3 y (483 d) N/A N/A
CD4 Count cells/ml TP2 774 629 at PBMC TP2 556 486 684
903 at GALT TP2
Plasma VL copies/ml TP2 ,20 ,20 at PBMC TP2 ,20 27,300 .100,000
,50 at GALT TP2
doi:10.1371/journal.ppat.1002506.t001
Absence of HIV-1 Evolution in the Gut
PLoS Pathogens | www.plospathogens.org 3 February 2012 | Volume 8 | Issue 2 | e1002506corresponding to the 2
nd PBMC sampling time point revealed all
individuals to have plasma HIV-1 viral loads of below 20 copies/
ml (Roche Taqman, v. 2.0). For individual IIA, GALT TP2
occurred approximately 1 year after PBMC TP2. Although
plasma HIV-1 RNA was determined to be ,50 copies/ml at
GALT TP2, no PBMCs or plasma were stored at GALT TP2 for
retrospective analysis. As a result, although the plasma HIV-1
RNA for IIA one year prior to GALT TP2 was clearly ,20
copies/ml, we were unable to determine if the plasma viral load
for this individual at GALT TP2 was also ,20 copies/ml.
Figure 1. Immunological profiles of experimental patients before and after initiation of cART. (A) Representative flow plots from low
immune activator patient (LIA) are depicted. CD8
+ T cells are shown on the x-axis and CD4
+ T cells on the y-axis. (B, C) Bar graphs depicting CD4:CD8
ratio (B) and levels of immune activation (C) of PBMC (red bars) and MMC (blue bars) before (PBMC1 and MMC1) and after (PBMC2 and MMC2)
initiation of antiretroviral therapy. High immune activator (HIA), intermediate immune activator (IIA) and low immune activator (LIA) are compared.
(D, E) Immunohistochemical characterization of immune effector sites in rectosigmoid biopsies. Using a PC-based image-analysis system (KS 4000,
Kontron) a standard area was set by the image analyzer. A total of between 10 and 15 consecutive non-overlapping fields were analyzed. In figure (D),
a biopsy section (viewed at 406magnification) compares CD4+ T cells (stained red) of subject IIA before (left panel) and after (right panel) initiation
of antiretroviral therapy. Figure (E) depicts mean CD4+ T before (LP1) and after (LP2) initiation of antiretroviral therapy. HIA, IIA and LIA are compared.
doi:10.1371/journal.ppat.1002506.g001
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(PBMCs) were obtained during their presentation with early HIV-
1 infection (Table 1). Both participants elected to remain naı ¨ve to
cART, and were continuously viremic to the second PBMC
sampling time point, 1.8 to 1.9 years later. Recto-sigmoid colonic
mucosal tissue sampling was not performed for the positive
controls.
Single Genome Amplification and Sequencing of HIV-1
envelope
Single genome amplification (SGA) of full-length HIV-1 env
(.2.5 kb) was performed on proviral genomic DNA from
cryopreserved PBMCs and GALT tissue where indicated for each
individual using a modification of the method of Salazar-Gonzalez
et al. [63,65]. A total of 378 confirmed single genome sequences
(SGS) from the three experimental and two positive control
patients were obtained as described in Methods. On average, 23
SGS were obtained per patient, per time-point, per compartment.
Phylogenetic analysis demonstrates that sequences from each
experimental and control patient form tight and distinct clusters
(Figure 2). This is consistent with the absence of contamination
between patient samples during PCR [66].
All experimental and control participants were found to harbor
HIV-1 Subtype B virus using the REGA HIV-1 subtyping tool
[67,68]. Along with CD4, HIV-1 typically uses the CCR5
chemokine coreceptor for entry early in infection [69]. Genotypic
changes allowing the virus to use CXCR4 have been associated
with the more rapid progression of HIV-1 disease [70]. Analysis of
translated HIV-1 V3 loop sequences for all viral quasispecies from
the positive controls and participants HIA and IIA were predicted
by the Web Position Specific Scoring Matrix (PSSM) tool (SINSI
matrix) to utilize the CCR5 HIV-1 co-receptor for viral entry
[71,72]. Interestingly, translated V3 loop sequences from individ-
ual LIA were predicted to use the CXCR4 co-receptor for viral
entry. The PSSM bioinformatic method has a reported sensitivity
of 84% sensitivity and 96% specificity for the prediction of
CXCR4 usage [72]. Given the relative infrequency of transmitted
CXCR4 virus [73–75], a cyropreserved pre-treatment plasma
specimen from LIA was sent for cell-based confirmation of co-
receptor usage for entry into CD4+ cells. The LIA plasma sample
submitted for the determination of HIV-1 tropism using the
monogram assay was collected on the same day as the pre-
treatment samples used for SGA of HIV-1 env from PBMC and
GALT in this individual. Using pseudotyped virus engineered to
express the LIA HIV-1 env, Trofile assays (Monogram Biosciences)
[76] reported a dual/mixed virus population with the ability to use
CXCR4 and/or CCR5 co-receptors to enter the CD4+ cell. The
reported relative light units (RLUs) for CCR5 and CXCR4 usage
in the population were 132,786 and 1,439 respectively (near the
limit of detection for CXCR4). Given the uniform predictions for
all LIA quasispecies in PSSM scoring, we concluded the LIA
viruses were likely to represent a dual mixed virus population with
the ability to utilize both co-receptors for cellular entry.
SGA of HIV-1 env reliably detects viral evolution in the
PBMCs of untreated patients
To demonstrate our ability to detect measurable viral evolution
when expected, we generated HIV-1 env SGS from the PBMCs of
two individuals who chose not to initiate cART during primary
HIV-1 infection. For these two cases, a total of 98 confirmed SGS
were obtained (43 for POS1 and 55 for POS2). Highlighter plots
(http://www.hiv.lanl.gov) were used to visualize individual
nucleotide polymorphisms within sequences under consideration
[77]. Both phylogenetic trees and Highlighter plots for each intra-
patient viral variant for POS1 and POS2 are shown (Figure 3). For
both individuals, SGA-derived full-length HIV-1 env sequences
unequivocally revealed that over time, in the absence of cART,
there is predictable diversification away from the virus population
initiating the infection.
The Tamura-Nei substitution model in MEGA 4.0.2 [78] was
used to calculate average pair-wise distances (APD) between intra-
patient HIV-1 env quasispecies. These calculations allowed for the
quantification of genetic diversity within and between PBMC
populations at each intra-patient time point. Several sequences
were found to have a high statistical likelihood (p,0.05) of GRA
hypermutations using the Hypermut program available via the Los
Alamos website [79]. In contrast to true sequence evolution,
hypermutations are believed to be the product of a single
replication cycle and as such, they cannot be regarded as evidence
of gradual sequence evolution [80,81]. As a result, these sequences
were excluded from quantitative determinations of genetic
diversity. For POS1 the average within-patient env nucleotide
diversity at PBMC time point #1 was 0.13% and increased to
1.23% by the time of the second PBMC sampling 1.9 years later.
For POS2, the within-patient env nucleotide diversity at PBMC
time point #1 was 1.11%. It has been estimated that the
maximum within-patient diversity plausibly developing from
infection with a single viral variant within 100 days is
approximately 0.6% [63]. The within-patient env nucleotide
diversity of 1.11% within 54 days of infection in POS2 therefore
suggests the transmission of more than one viral variant in this
case. Examination of the maximum likelihood (ML) phylogenetic
tree and Highlighter analysis (Figure 3) for this individual was
consistent with this hypothesis, as several distinct sequence clusters
with ML bootstrap values .85% supported the transmission of
more than one viral variant. The high multiplicity of HIV-1
infection in this individual is compatible with previous results by Li
et al, in which SGA of HIV-1 env revealed 36% of their men who
have sex with men (MSM) cohort to have evidence of productive
infection with more than one HIV-1 Subtype B virus [82]. At the
time of the second PBMC time point 1.8 years later, the within-
patient env nucleotide diversity in this individual was found to be
1.08%. To quantify the amount of evolution that occurred during
the time interval studied, we determined the APD between SGS
obtained from ARV naı ¨ve time points #1 and #2. For POS1, the
experimentally observed HIV-1 env nucleotide diversity between
the two time points was 1.68%. For POS2, given the evidence of
infection with more than one viral variant, we conservatively
compared the APD between a monophyletic subset of time point
#1 SGS phylogenetically closest to the time point #2 sequences
(labeled Variant 1 in Figure 3) and the time point #2 sequences.
Using this approach, the HIV-1 env nucleotide diversity between
the two time points was 1.36%. Given a published rate of
evolution of the C2-V5 region of the HIV-1 env gene of
approximately 1.0% per year [83], the experimentally observed
env nucleotide diversity between PBMC time points #1 and #2 for
each individual are within the expected range for evolving viral
quasispecies over a period of 1.8 (POS2) to 1.9 (POS1) years.
Altogether, these results demonstrate our ability to detect
evolution using SGA when multiple replication cycles have
occurred in untreated patients.
Maximum-likelihood phylogenetic trees of SGA-derived
HIV-1 env do not reveal viral evolution in the GALT or
PBMC of patients during suppressive cART
As detailed above, the three study subjects achieved a significant
degree of immune reconstitution in the peripheral blood based on
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activation and CD4+ T cell depletion in the GALT was the result
of local ongoing virus replication, evolution of GALT-derived
HIV-1 env would be most likely to occur in the individual with the
highest levels of residual immune activation and lowest level of
immune reconstitution despite cART. Therefore, we anticipated
that if we were to observe measurable evolution of viral
quasispecies during cART, that two scenarios would be apparent:
(1) The amount of evolutionary divergence between GALT-
derived HIV-1 env populations sampled 1–2 years apart would be
greater than between longitudinal, contemporaneous PBMC-
derived HIV-1 env populations and (2) The amount of genetic
diversity developing in an individual’s GALT-derived HIV-1 env
quasispecies over time would correlate positively with the level of
immune activation and CD4+ T cell depletion measured
experimentally. As a result, we would expect the greatest amount
of within-patient evolution of HIV-1 viral quasispecies to occur in
HIA, followed by IIA, with the lowest levels of evolution in LIA.
Phylogenetic analyses were first used to estimate sequence
divergence as described for the positive control cases. Figure 4
shows the ML trees with bootstrap values for HIV-1 env sequences
derived from pre- and post-treatment PBMC and GALT for
participants HIA, IIA and LIA. Corresponding Highlighter plots
allow for visualization of individual nucleotide polymorphisms
within sequences under consideration [77]. Visual inspection of
maximum likelihood phylogenetic trees and Highlighter plots of full
length HIV-1 env clearly reveal highly homogeneous viral
populations during early HIV-1 infection in both the PBMC
and GALT immediately prior to the initiation of cART for
individuals HIA and LIA. This is consistent with productive
infection in these individuals with a single virus. In each individual,
there is a high degree of similarity between SGA-derived HIV-1
env sequences from each compartment within the viral variants
establishing primary infection. In contrast to what is observed in
the absence of cART, the population structure of these ML trees
demonstrates no visual evidence of evolutionary diversification
away from the virus populations identified during primary
infection after 1–2 yrs of suppressive cART in either the PBMC
or GALT. Using the same sequence alignments, phylogenetic trees
were also generated using the neighbor-joining method [84]
implemented in the MEGA program Version 4.0 [78] (data not
shown). Bayesian estimation of phylogenies for experimental and
control individuals were also generated using MrBayes 3.1.2 [85]
yielding similar population structure results (Figure S1).
SGA followed by phylogenetic analysis indicates that individual
IIA was productively infected with a minimum of two, and
possibly three distinct HIV-1 viral variants. In this individual, a
small number of in-vivo inter-lineage recombinant viruses
(Figure 4B and Table S1) were detected through visual
interrogation of the Highlighter plot. The Hudson-Kaplan test
[86] implemented in the DnaSP software [87] found a minimum
of 9 recombination breakpoints among the recombinant sequenc-
es. Recombination breakpoints were confirmed and corresponding
levels of significance determined using the Recco program [88]
(Table S1). The noted recombinants were observed in both the
PBMC and GALT and at both time points analyzed. Recombi-
nation of HIV-1 env quasispecies results in non-clock genetic
evolution that can incorrectly bias quantitative estimates of
population divergence [89]. Additionally, owing to their relative
rarity in the population of HIV-1 envs sampled from participant
IIA, the recombinants sampled 1–2 years into cART are just as
likely to have been present at the initial sampling time point and
therefore do not represent evidence of viral evolution during
suppressive cART.
Quantitative estimates of HIV-1 env population diversity
and divergence do not reveal viral evolution in the GALT
or PBMC of experimental patients during suppressive
cART
Evidence for the absence of HIV-1 env evolution in the PBMC
and GALT of the three experimental individuals, regardless of
level of residual GALT immune activation or CD4+ T cell
depletion is readily found in the phylograms and Highlighter plots
(Figure 4). In an effort to quantify evolutionary relationships
represented in the phylogenetic trees, we determined estimates of
population diversity and divergence over sequence pairs within
and between groups by measurement of average pairwise distances
(APDs). As in the positive control group, sequences with a
significant probability of hypermutation were excluded from this
analysis.
To detect statistically significant shifts in population structure
that might not be evident from APD calculations alone, we used a
nonparameteric test for panmixia [90]. This test was derived from
a geographic subdivision detection test proposed by Hudson et al.
[91]. In an investigation of viral evolutionary divergence in the
SIV/pigtail macaque model [92], p,10
4 was used as a significance
threshold for panmixia. This stringent p- value threshold was
chosen to correct for multiple nucleotide comparisons and make
panmixia detection robust to potential sampling error by SGS
[92]. In this analysis, we have instead chosen to fix the p value
threshold for panmixia at p,0.05, apply a Bonferroni correction
to p-values obtained from testing of multiple compartments across
time points, and require a second, confirmatory test to infer true
shifts in population structure in a sample.
The second test used for analysis of population structure was the
Slatkin-Maddison (SM) test [93]. Implemented in HyPhy [94].
Given an input tree and predefined groups of sequences in that
tree, the SM test uses parsimony to determine the number of
migration events, i.e. the number of times a sequence from one
group migrated to another group; the observed number of
migrations - the degree of intercompartment segregation - is then
compared to a null distribution obtained by repeated shuffling
(1000 iterations) of the group assignments. This approach applies a
parsimony criterion to the evolution of each character on the
maximum likelihood gene phylogeny in question, and assesses the
degree of variation from the normal distribution of simulated
sequences over the tree to assess the degree of intercompartment
segregation.
The number of base substitutions per site averaged over all
sequence pairs both within and between groups is shown as well as
results for tests of panmixia (Tables 2 and 3). As the diversity
between viral lineages at transmission represents mutations
accumulated in the donor, the determination of viral evolution
as a function of changes in genetic diversity is only valid when
Figure 2. Intra-Patient clustering of HIV-1 env quasi-species. Maximum Likelihood (ML) tree depicting full-length HIV-1 env sequences from
three experimental subjects (HIA, IIA, LIA) and 2 positive control subjects (POS1 and POS2). For each subject, all sequences from both time-points
(baseline and on treatment) and from all compartments described are shown. Bootstrap values (.95%) are shown for inter-subject clusters. 1000
bootstrap replicates were run and Bootstrap values over 85% are shown. The horizontal scale bar represents 2.0% genetic distance. Each subject
forms a tight cluster and is distinct from other experimental subjects or controls. HXB2 was used as an outgroup.
doi:10.1371/journal.ppat.1002506.g002
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a result, for participant IIA, only one distinct group of sequences
corresponding to one of the multiple infecting viral variants
demonstrated in Figure 4B was considered following the removal
of both hypermutated and recombinant viral variants: population
(Variant 1) with 48 SGS (Figure 4B and Table 3). Given the need
to further distinguish between SGA-derived HIV-1 env quasispe-
cies obtained from PBMC pre- and post-cART and GALT pre-
and post-cART, remaining populations contained too few
sequences in each compartment for meaningful quantitative and
statistical analyses. As a result, only the largest of the IIA infecting
populations (Variant 1) was analyzed (Table 3). Similarly, given
evidence of multiple infecting viral variants for POS2 (each with a
small number of variants), statistical analysis for POS2 could not
be performed (Table 2).
In the event of ongoing viral replication resulting in viral
evolution, we would expect to document the all of the following as
seen for POS1: (1) Increasing nucleotide diversity within groups
over time (increases in within-group APD between time point #1
(TP1) and time point #2 (TP2); (2) Between group (BG) APDs
consistent with nucleotide divergence between groups over time
and; (3) Significant p- values for tests of panmixia reflecting
significant population divergence over time. (4) Significant p-values
for confirmatory Slatkin-Maddison test reflecting true differences
in population structure.
Average pairwise distances within PBMC groups during early
HIV-1 infection for HIA, IIA (infecting variant #1) and LIA were
expectedly low (0.0011, 0.0006 and 0.0012 respectively) (Table 3).
At the second time point after 1.1 to 1.3 years of suppressive
cART, within group APDs remained low for each individual but
were slightly increased for HIA (0.0015) and decreased for both
IIA (0.0005) and LIA (0.0008). In each individual, tests of
panmixia between PBMC TP1 and PBMC TP2 yielded non-
significant p-values, indicating a clear mixing of populations and
providing assurance that the measured values for between group
APDs (BG APDs) were not large enough to represent statistically
significant nucleotide divergence between the populations. As a
result, we conclude that the small increase in within group APD
from PBMC TP2 SGS for HIA is not large enough to represent
evidence of viral evolution over time, and the small decrease in
within group APD from PBMC SGS for IIA and LIA does not
represent evidence of loss of viral diversity over time.
Average pairwise distance determinations within and between
GALT groups for HIA reveal a similar story. During early HIV-1
infection, GALT populations in HIA, IIA (Variant 1) and LIA
were also homogenous, with low APDs within populations of
infecting quasispecies (0.0009 for HIA, 0.0005 for IIA Variant 1
and 0.0014 for LIA). In the case of HIA, the average within-
GALT nucleotide distance prior to the initiation of cART was
0.0009. Following 1.3 years of cART, the average within-group
nucleotide distance was 0.0007. Sequence compartmentalization
between GALT TP1 and TP2 was supported by the test of
panmixia (p=0.027). However, confirmatory testing using the
Slatkin-Maddison test revealed no significant evidence of
population structure in the GALT compartment (p=0.780) or
over the entire phylogenetic tree as a whole (p=0.589). This
finding, combined with the low APD between GALT TP1 and
TP2 (0.0008) and absence of an increase in GALT viral diversity
allowed us to conclude that the numerical decrease in the within
group APD was not reflective of a significant loss of viral diversity
in the GALT of participant HIA at the second time point, and
that there was no evidence of HIV-1 env evolution in the GALT
from the individual we hypothesized most likely to exhibit
residual HIV-1 replication in this compartment given their
immunologic profile 1.3 years after the initiation of cART
(highest degree of GALT immune activation and lowest degree of
CD4+ T cell reconstitution).
For IIA, we saw a similar decrease in within group APD
between GALT TP1 (0.0005) and GALT TP2, (0.0002) arguing
against any evidence of viral evolution in this compartment due to
viral replication. However, given the small number of SGS in
GALT TP 2 for this variant (,10 SGS), the high potential for
sampling error prevented us from performing a statistical test of
panmixia between these two groups. As a result, we were unable to
determine if the measured decrease in within-group GALT TP2
viral diversity was indicative of a significant loss of diversity over
time. Slatkin-Maddison testing for the IIA Variant 1 phylogram
(with GALT TP2 sequences removed) was non-significant
(p=0.078).
Finally, for LIA, the within-group APDs for GALT TP1
(0.0014) and GALT TP2 (0.0007) SGSs again fails to reveal an
increase in HIV-1 env diversity over time. However, the panmixia
probability for this compartment is significant (p=0.003) and
confirmed by Slatkin-Maddison testing (p,0.001) of the compart-
ment, and of the complete phylogram (p,0.001). Statistical tests of
population structure across all compartments and across all time
points for this individual reveals significant compartmentalization
using both the panmixia and Slatkin-Maddison tests only for those
compartments that are compared against GALT TP1. Evaluation
of the phylogram and Highlighter plots demonstrates a number of
identical (monotypic) sequences. Given this observation, and the
knowledge that statistical estimates of compartmentalization can
be biased by identical sequences [95–98], we then collapsed
identical sequences into a single sequence within each compart-
ment, at each time point. Repeat Slatkin-Maddison testing on the
reconstructed maximum-likelihood phylogram revealed the ab-
sence of any significant population structure in the tree (p=0.086).
As mentioned earlier, evaluation of pre-treatment plasma and
proviral DNA sequences revealed that patient LIA was infected
with a dual-tropic HIV-1 variant capable of using both CCR5 and
CXCR4 for cellular entry. The extent, if any, to which this may
have influenced the expansion of pre-treatment variants in the
GALT, where the target cells are overwhelmingly CD4+CCR5+ is
unclear.
When compared to their corresponding PBMC population at
TP1, low between group APDs and non-significant p-values for
tests of panmixia reveals the absence of compartmentalization
between HIV-1 env variants in PBMC and GALT during early
infection with HIV-1 for individuals HIA and IIA (Variant 1).
Following removal of duplicate sequences in the phylogeny, this is
true for LIA as well.
Figure 3. Evolution of HIV-1 env in the absence of cART – positive control patients. ML tree of SGA sequences from (A) positive control
subject 1 (POS1) and (B) positive control subject 2 (POS2). For both panels, PBMC time point #1 (open red circles) and PBMC time point #2 (closed
red circles) are shown. 1000 bootstrap replicates were run and Bootstrap values over 85% are shown. The scale bar represents 0.005 nucleotide
substitutions per site. HXB2 was used as an outgroup. Starred sequences represent those determined to be hypermutated. On the right is a
Highlighter plot corresponding to the ML tree (outgroup sequence not shown). Individual nucleotide changes from a master sequence (TP1
sequence at the top of the ML tree) are shown. A-green; T-red; G-orange; C-light blue. For participant POS2, phylogenetic analysis reveals acquisition
of more than one variant as shown.
doi:10.1371/journal.ppat.1002506.g003
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mum-likelihood phylogenies and Highlighter plots, these results
provide no evidence of significant evolution of HIV-1 env in the
PBMC or GALT of individuals initiating cART during early
HIV-1 infection. Additionally, this data provides no evidence
that levels of immune activation in the GALT at time points
during which viral suppression has been achieved in the
periphery is associated with or predictive of any degree of viral
evolution.
Discussion
In this study we have shown that in a group of HIV-1 infected
individuals initiating therapy during early infection, no evidence
of substantial viral evolution could be found in HIV-1 env variants
derived from the peripheral blood mononuclear cells or gut-
associated lymphoid tissue after 1–2 years of suppressive cART.
We initially hypothesized that if continued HIV-1 replication in
the GALT was responsible for persistent immune activation in
Figure 4. HIV-1 env phylogenies do not suggest measurable evolution on suppressive cART. ML tree of SGA sequences from participants
(A) HIA (B) IIA and (C) LIA. For all panels, PBMC time point #1 (open red circles), PBMC time point #2 (closed red circles), GALT time point #1 (open
blue squares) and GALT time point #2 (closed blue squares) are shown. 1000 bootstrap replicates were run and Bootstrap values over 85% are
shown. The scale bar represents 0.005 nucleotide substitutions per site. HXB2 was used as an outgroup. Starred sequences represent those
determined to be hypermutated. To the right of each ML tree is the corresponding Highlighter plot (outgroup sequence not shown). Individual
nucleotide changes from a master sequence (TP1 sequence at the top of the ML tree) are shown. A-green; T-red; G-orange; C-light blue. For
participant IIA, phylogenetic analysis reveals acquisition of more than one variant with in-vivo inter-lineage recombinants. Sequences surrounded by
boxes represent HIV-1 env recombinants (red boxes denote a sequence p value of p,0.05 in Recco; black boxes denote a sequence p value of p,0.25
in Recco).
doi:10.1371/journal.ppat.1002506.g004
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correlate positively with experimentally determined levels of
GALT immune activation, while correlating negatively with
levels of immune reconstitution. In the absence of quantifiable
evolution in any of the three carefully selected individuals
characterized as having High, Intermediate, or Low levels of
Immune activation, we find no evidence to support our initial
hypothesis. In an effort to make the search for evolution as
rigorous as possible, this research utilized the single genome
amplification (SGA) technique to generate HIV-1 variant
sequences. SGA has been shown to decrease Taq-induced
recombination, template resampling, nucleotide misincorporation
and cloning bias when compared to more conventional
sequencing methods [55–57,60–62]. The use of this method
therefore produces a more accurate representation of in-vivo HIV-
1 quasispecies and this work represents the first application of the
SGA method to an evolutionary study of GALT-derived HIV-1
full-length HIV-1 env populations.
Controversy in the field regarding the ability of suppressive
cART to prevent ongoing cycles of HIV-1 replication remains. In
the recent literature, the majority of studies using phylogenetic
methods have suggested the absence of HIV-1 evolution in
patients undergoing suppressive cART [51–53] although dissent-
ing findings exist [45]. Recent literature using alternative
experimental methods such as measuring the accumulation of 2-
LTR circles in the periphery during intensification of cART-
suppressed individuals suggests ongoing replication [41]. These
findings however, are also controversial, as other recent intensi-
fication studies in patients on suppressive cART have shown no
effect on endpoints such as plasma HIV-1 RNA levels or T cell
activation in the PBMCs or sigmoid colon in HIV-infected
patients with a suboptimal CD4+ T cell response [99] as well as no
Table 2. Nucleotide distance calculations with panmixia and Slatkin-Maddison (SM) probabilities-positive controls.
Participant Compartment PBMC TP1 Within Group APD p SM #SGS
BG APD p Panmixia
POS1 PBMC TP1 - - 0.0013 ,0.001* [,0.001*] 18 [12]
POS1 PBMC TP2 0.0168 ,0.0001* 0.0123 - 22 [22]
POS2 PBMC TP1 - - 0.0004 N/A 6
POS2 PBMC TP2 0.0136 N/A 0.0108 - 28
Nucleotide Distance Calculations with panmixia and Slatkin-Maddison (SM) probabilities for positive control (POS1 and POS2) patients. BG=Between Group,
APD=Average Pairwise Distance and SM=Slatkin-Maddison Test. #SGS=number of sequences used per compartment in analysis after exclusion of hypermutated and
recombinant sequences. For probability of panmixia, p-values,0.05 are considered significant. For POS2 analysis for only one infectious variant is shown. #SGS in
brackets for POS1 denote number of unique sequences used in Slatkin-Maddison Test. Bracketed Slatkin-Maddison probabilities denotes p SM following removal of
duplicate sequences.
*=Statistically significant; N/A=Not applicable.
doi:10.1371/journal.ppat.1002506.t002
Table 3. Nucleotide distance calculations with panmixia and Slatkin-Maddison (SM) probabilities – experimental cases.
Participant Compartment PBMC TP1 PBMC TP2 GALT TP1
Within
Group
APD p SM #SGS
BG APD p Panmixia BG APD p Panmixia BG APD p Panmixia
HIA PBMC TP1 - - - - - - 0.0011 0.589 26
HIA PBMC TP2 0.0013 1.0 - - - - 0.0015 - 19
HIA GALT TP1 0.0010 1.0 0.0012 0.526 - - 0.0009 - 22
HIA GALT TP2 0.0009 1.0 0.0011 1.0 0.0008 0.027* 0.0007 - 23
IIA PBMC TP1 - - - - - - 0.0006 0.078 14
IIA PBMC TP2 0.0006 0.206 - - - - 0.0005 - 10
IIA GALT TP1 0.0006 0.382 0.0005 0.134 - - 0.0005 - 20
IIA GALT TP2 0.0004 N/A 0.0004 N/A 0.0004 N/A 0.0002 - 4
LIA PBMC TP1 - - - - - - 0.0012 ,0.001*
[0.086]
27 [19]
LIA PBMC TP2 0.0010 0.385 - - - - 0.0008 - 22 [13]
LIA GALT TP1 0.0013 0.042* 0.0012 0.005* - - 0.0014 - 26 [23]
LIA GALT TP2 0.0009 0.171 0.0008 0.157 0.0011 0.003* 0.0007 - 19 [10]
Nucleotide Distance Calculations with panmixia and Slatkin-Maddison (SM) probabilities for experimental patients (HIA, IIA and LIA) are shown. BG=Between Group,
APD=Average Pairwise Distance and SM=Slatkin-Maddison Test. #SGS=number of sequences used per compartment in analysis after exclusion of hypermutated and
recombinant sequences. For probability of panmixia, p-values,0.05 are considered significant. For IIA, analysis for only one infectious variant is shown. #SGS in
brackets for LIA denote number of unique sequences used in Slatkin-Maddison Test. Bracketed Slatkin-Maddison probabilities denotes p SM following removal of
duplicate sequences.
*=Statistically significant; N/A=Not applicable.
doi:10.1371/journal.ppat.1002506.t003
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Examining the effect of intensification of suppressive cART with
the integrase-inhibitor raltegravir, Yukl et al. concluded that in
addition to effecting no significant decrease in HIV-1 RNA in
plasma, no HIV-1 RNA decreases were noted in the duodenum,
colon or rectum [101]. In contrast, the authors did report a
decrease in unspliced HIV-1 RNA per 10 CD4+ T cells in the
ileum in the majority of patients studied. These data suggest that if
the GI tract does have the ability to act as a reservoir for HIV-1
replication, that ability may be compartmentalized to areas outside
of the recto-sigmoid colon investigated in our work. One may also
consider that although robust phylogenetic studies may not reveal
evidence of viral evolution during cART, the ability to identify
ongoing HIV-1 replication during suppressive cART may be
possible using other experimental methods.
With regards to the more specific question of whether or not the
GALT serves as a reservoir for continued viral replication in the
presence of cART, our findings are consistent with those of two
recent phylogenetic studies examining this unique compartment.
Imamichi et al. [102] examined compartmental differences
between two sites in the gut (colon and terminal ileum) and
peripheral blood in chronically infected HIV+ individuals.
Contemporaneous intra-patient clonal sequences spanning the
C2-V3 region of the HIV-1 env gene were examined from cell-
associated DNA and RNA and virion RNA. Phylogenetic analysis
revealed no evidence of compartmentalization of HIV-1 between
the gut and peripheral blood and in two individuals, neighbor-
joining trees revealed no indication of viral evolution during 12
months of suppressive cART. Additionally, Lerner et al. conclude
through the bulk sequencing of GALT-derived viral variants
rebounding from individuals interrupting cART after initiation of
cART during primary HIV-1, that GALT was unlikely to be a
major contributor to post-interruption plasma viremia [103].
In the presence of cART, the plasma viral burden is decreased
from 4–6 log in our study participants. As a result, the scale of
expected evolutionary change is perhaps less than would be
expected in the absence of ART. Several studies have looked at
HIV-1 env replication at this lower limit of detection and their
findings are informative. Mens et al. looked at evolutionary rates of
HIV-1 pro-rt and env in longitudinal samples from HIV-1
controllers with median plasma HIV-1 RNA levels of 0.3 to 0.8
copies/ml and found evidence of ongoing replication [89] based
on increasing viral divergence over time. In addition, while levels
of viremia in the HIV-1 non-controllers was significantly higher
than that of the HIV-1 controllers studied, the measured rates of
evolution of HIV-1 env were not very different in the groups. Also,
in a recent study by Anderson et al. [104] SGS-derived HIV-1 envs
from the plasma of two individuals on suppressive cART with low
level viremia was found to be identical to HIV-1 env sequences
recovered from outgrowth assays from pools of resting CD4+ T
cells. Finally, in the SIV model, Kearney et al. found that in well-
suppressed pathogenic SIV infection, those animals with SIV
RNA viral load ,20copies/ml showed no evidence of evolution in
the SIV pol in plasma over a 20 week period [92].
The extent to which the dual tropic nature of the infecting virus
in the low immune activator (LIA) patient may have influenced the
overall burden of HIV-1 infection in the GALT and subsequent
levels of immune activation in that compartment (given that the
preferred targets for HIV-1 infection are believed to be mucosal
CCR5+ memory CD4+ T cells [20,27,28]) is unclear. While
removal of duplicate sequences in the LIA phylogram abolished
any statistical evidence of compartmentalization between tissues
(PBMC vs GALT) and time points (pre- and during- cART), we
also must consider the extent to which the elimination of these
sequences may have altered the power to detect real differences in
the dataset. Known differences in HIV-1 co-receptor expression
on CD4+ T cells of the peripheral blood and GI tract, coupled
with the dual tropic nature of the infecting viral population in this
individual could make compartmentalization at the time of
infection between variants in the PBMC and GALT a possibility.
Persistence would in our minds more likely reflect a founder effect
as opposed to evidence of the generation of viral diversity over
time given the absence of evolution on the phylogram, as well as a
failure of the sequences to increase in diversity. It is also interesting
that for subject IIA, there is an apparent difference in distribution
of sequence types among the two or three potential clusters
between GALT TP1 and GALT TP2. Based on the amount of
dilution necessary to generate single genomes, HIV DNA levels in
the GALT of this individual were approximately ,806lower in
TP2 than in TP1. We hypothesize that this apparent shift in
GALT populations may be a reflection of selective clearance of
target cells (perhaps a particular subtype of target cell) in the
GALT initially harboring a population of viral variants. We do
also have to consider, particularly in the face of dramatic declines
in HIV-1 DNA in this compartment, that the apparent
phylogenetic shift may reflect under-sampling of the compartment.
Limitations of the present study include the generation of
sequence data using genomic DNA as the template. This was
experimentally necessary; given the need to generate multiple
HIV-1 env variants from GALT specimens obtained in the setting
of plasma HIV-1 RNA levels ,50 copies/ml. As a result, one must
consider that the sampling of approximately 20 to 25 DNA
sequences per tissue per time point from a provirus population
may have hindered our ability to adequately detect and sample
from the small subset of infected cells containing replication
competent virus. Use of viral RNA would more accurately limit
the population sampled to those env sequences derived from
replication competent virus at the time of sampling. However,
inclusion of archived variants in the studied population should not
have been expected to preclude the discovery of evolved variants if
they existed. It is also important to note the small number of
subjects studied to date (3 experimental and 2 positive control
individuals), as well as the relatively short duration of cART in
these studies. Characterization of the study individuals using
immune activation phenotypes at only one time point on
suppressive cART, as well as the absence of more than one time
point following viral suppression for the generation of SGS are
further experimental limitations of note. Additional work on the
generation of a model of expected levels of evolution in the
presence of HAART would be informative. Furthermore, the
experiments we report here involve the SGA of full length HIV-1
env. This method was chosen because it interrogates a significant
fraction (.2.5 kb) of the viral genome that has been shown to
evolve at a measurable rate in a number of publications utilizing
the SGA technique. We cannot, however, rule out the possibility
that we might have been able to document evidence of evolution
in other regions of HIV-1 such as gag, pol or nef had they been
interrogated. Also, as mucosal biopsy sampling does lead to some
degree of bleeding into the tissues, we cannot fully exclude the
possibility of some contamination of GALT tissue samples with
contemporaneous PBMC. While this may lead to appearance of
PBMC derived SGS appearing in the GALT compartment, it does
not explain the absence of evolving forms from GALT founder
sequences.
Finally, an important consideration in these studies is the unique
nature of the study population. In each of the cases, participants
were identified during acute/early HIV-1 infection, and in the
case of the experimental subjects, initiated cART during this
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during the chronic phase of infection. It is possible that the
findings in our group of individuals cannot be completely
generalized to a greater population initiating cART at later time
points, with a higher degree of pre-treatment diversity and
potentially larger pool of latent CD4+ T cells. However, for this
work, the study of individuals initiating therapy during primary
infection is preferred, as interpretation of longitudinal nucleotide
changes is greatly facilitated by knowledge of the viral quasispecies
present close to the time of viral acquisition.
In summary, our data is consistent with the observations made
by others suggesting that the success of cART is due to the
complete or nearly complete suppression of viral replication
achieved with cART [105,106]. Using the robust technique of
SGS of full length HIV-1 env, we were unable to identify evolved
forms in the PBMC or GALT of individuals with known
immunologic evidence of residual GALT immune activation
despite clinical evidence of plasma HIV-1 RNA suppression. The
absence of evidence of evolved HIV-1 variants during cART
described in the present study supports the conclusion that at a
minimum, currently available regimens of suppressive cART have
the ability to abrogate de-novo rounds of HIV-1 replication in the
gastrointestinal lymphoid tissue in individuals initiating such
therapy during primary infection.
Materials and Methods
Ethics statement
This study was approved by the Institutional Review Board of
the Rockefeller University (New York, New York, United States).
All participants provided written informed consent prior to sample
acquisition and all clinical investigation was conducted according
to the principles expressed in the Declaration of Helsinki.
Study subjects and sample acquisition
Study subjects were chosen from the Aaron Diamond AIDS
Research Center Acute Infection Program. All study individuals
self-identified as men who have sex with men (MSM) and had a
clinical history consistent with the acquisition of HIV-1 during
sexual contact. Duration of infection at presentation was estimated
as 2 weeks prior to the onset of acute retroviral illness.
Serum specimens were tested for viral specific antibodies using
the HIV-1/HIV-2 PLUS O enzyme immunoassay (EIA) and
Vironostika less sensitive (LS) EIA (the serologic testing algorithm
for recent HIV seroconversion [STARHS]). HIV-1 Western Blots
were performed by the Public Health Laboratory of the City of
New York Department of Health and Mental Hygiene. Plasma
samples were tested for HIV-1 RNA and by routine commercial
testing battery including the Roche Cobas Amplicor HIV-1
Monitor Test version 1.5 and the Roche COBAS AmpliPrep/
COBAS TaqMan 48 System with AmpliLink Software Version
3.2 as per manufacturer’s instructions. These results were used to
stage subjects according to the Fiebig classification system for
acute and early HIV-1 infection [107].
Contemporaneous peripheral blood and recto-sigmoid colonic
mucosal tissue samples were obtained from three cART-naı ¨ve,
HIV-1 seropositive males identified during acute/early HIV-1
infection. Positive control peripheral blood samples were obtained
from two additional cART-naı ¨ve, HIV-1 seropositive males
identified during acute/early HIV-1 infection. All participants
were enrolled with a nonreactive detuned ELISA result or a
documented negative HIV-1 test within the 6 months of biopsy.
Endoscopic biopsies were obtained from the colon from
macroscopically normal mucosa in all cases via flexible sigmoid-
oscopy and processed as previously described [30]. Briefly, the
biopsies were taken using large-cup endoscopic-biopsy forceps
(Microvasive Radial Jaw, Boston Scientific, Boston, Massachusetts,
United States) (outside diameter 3.3 mm) and (1) placed
immediately in tissue-culture medium (RPMI 1640, Mediatech,
Herndon, Virginia, United States); (2) placed into 2-ml pre-labeled
cryovials (Nalgene, Rochester, New York, United States) and
immediately frozen in liquid nitrogen; or (3) placed in formalin to
preserve tissue architecture. Formalin-fixed tissues were washed
with phosphate-buffered saline (PBS), transferred to 100% alcohol
and processed for immunohistochemistry. Endoscopic biopsies
were not obtained for the two positive control participants.
Phlebotomy was undertaken immediately prior to endoscopy
where applicable.
Immediately after acquisition, mucosal mononuclear cells
(MMCs) were enzymatically isolated from mucosal biopsies using
a 30-min incubation in collagenase type II (Clostridio-peptidase A,
Sigma-Aldrich, St. Louis, Missouri, United States) followed by
mechanical separation through a blunt ended 16-gauge needle.
The digested cell suspension was strained through a 70-mm
disposable plastic strainer. Immediately after isolation, cells were
washed with PBS and resuspended in PBS containing antibodies
for flow cytometry. Peripheral blood mononuclear cells (PBMCs)
were prepared by centrifugation on a Ficoll-Hypaque density
gradient (Mediatech).
At protocol defined participant visits, PBMCs were also stored
at 270 C in 1 ml of freezing media (10% DMSO 90% FCS) for
genomic DNA isolation at a later time.
Flow cytometry
Cell surface expression of lymphocyte antigens was performed
as previously described [30]. Briefly, freshly isolated MMCs were
subject to monoclonal antibody staining, followed by flow
cytometry using a FACSCalibur (Becton-Dickinson, Palo Alto,
California, United States) with analysis using CellQuest software
(Becton-Dickinson). Monoclonal antibodies used in this study
included: anti-human CD3-fluorescein isothiocyanate (FITC)
(clone UCHT1; Becton-Dickinson), anti-human CD3-phycoery-
thrin (PE) (clone SK-7; Becton-Dickinson), anti-human CD3-
peridinin chlorophyll-a protein (PerCP) (clone SK-7; Becton-
Dickinson), anti-human CD4-allophycocyanin (clone RPA T4;
PharMingen, San Diego, California, United States), anti-human
CD8 PE (clone RPA T8; PharMingen), anti-human HLA-DR
PerCP (clone L243; BD Biosciences Pharmingen), anti-human
CD45RO PE-Cy7 (clone UCHL1, BD Biosciences Pharmingen)
and the appropriate isotype controls. During flow cytometry,
lymphocytes, initially identified by their forward- and side-scatter
characteristics, were subject to phenotypic analysis. Dead cells
were excluded from analysis using 7-aminoactinomycin D
(Calbiochem, San Diego, California, United States). To determine
the percentages of CD4
+ and CD8
+ cells in the T cell population,
gated lymphocytes were initially examined for the expression of
CD3. The CD3
+ lymphocytes were then analyzed for expression
of CD4 and CD8 receptors. To examine for activated memory
cells, gated CD8
+ lymphocytes were examined for the expression
of CD45RO and HLA-DR.
Light microscopy and immunohistochemistry
Endoscopic biopsy tissue sample were fixed in 4% neutral-
buffered formalin and embedded in paraffin. Sections (of 5 mm
thickness) were cut and stained with hematoxylin-and-eosin and
Giemsa stains for light-microscopic evaluation. Immunohisto-
chemistry was performed on paraffin-embedded sections after
high-temperature antigen retrieval as previously described [30].
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CD4 (NCL-CD4-IF6, Novocastra Laboratories, Newcastle-upon-
Tyne, United Kingdom) or to 1:100 dilution of antibody to CD8
(C8/144B, DakoCytomaton, Glostrup, Denmark) for 60 min,
followed by incubation with a 1:20 dilution of rabbit anti-mouse
secondary antibody (DakoCytomaton code 259) for 20 min. The
tertiary antibody (APAAP-Complex Monoclonal Mouse, Dako-
Cytomaton) was applied in 1:50 dilution. The incubations were
carried out at room temperature and were followed by rinsing in
Tris-buffered saline (pH 7.4) for 5 min each. The alkaline
phosphatase was revealed by New Fuchsin as the chromogen.
CD4
+ or CD8
+ cells in the LP (effector site) and the organized
lymphoid tissue (OLT) (inductive site) were quantified separately.
Using a 406objective, a standard area was set (unit area), and a
photomicrograph was taken with a Zeiss AxioImager M1
microscope equipped with AxioCam MRc5 digital camera (Zeiss,
Jena, Germany). Fifteen nonoverlapping unit areas were selected
for the LP. Using AxioVision (Release 4.5) software (Zeiss),
positive cells showing lymphocyte morphology were counted.
Proviral DNA extraction and Single Genome
Amplification
Total genomic DNA from cryopreserved PBMCs from all
participants and GALT from experimental participants was
extracted by routine methods using the QIAamp DNA Mini Kit
(QIAGEN, USA). To minimize the risk of within-patient cross
contamination of samples, only one participant sample from one
compartment (PBMC or GALT) and time point was processed on
any given day.
Following limiting-dilution, single proviral molecules of full-
length HIV-1 subtype B env gene (.2.5 kb) were amplified by
nested PCR using a modification of the SGA method of Salazar-
Gonzalez et al. [63,108]. Briefly, genomic DNA was serially
diluted and distributed in replicates of 10 PCR reactions in
MicroAmp 96-well plates (Applied Biosystems, Foster City, CA).
Poisson distribution dictates that the DNA dilution that yields
PCR products in no more than 30% of wells contains one
amplifiable DNA template per positive PCR more than 80% of
the time [63]. Therefore, genomic DNA was endpoint diluted in
96-well plates such that fewer than 30% of the PCRs yielded an
amplification product. Additional PCR amplifications were
performed using this dilution in 96-well reaction plates. PCR
amplification was carried out in presence of 16 High Fidelity
Platinum Taq PCR buffer, 2 mM MgSO4, 0.2 mM each
deoxynucleoside triphosphate, 0.2 uM each primer, and 0.025
units/ul of Platinum Taq High Fidelity polymerase in a 20-ul
reaction (Invitrogen, Carlsbad, CA). The nested primers for
generating full length env were as follows: 1
st round sense primer
env5out 59-TAGAGCCCTGGAAGCATCCAGGAAG-39,1
st
round antisense primer env3out 59- TTGCTACTTGT-
GATTGCTCCATGT-39,2
nd round sense primer env5in 59-
TTAGGCATCTCCTATGGCAGGAAGAAG-39 and 2
nd round
antisense primer env3in 59-GTCTCGAGATACTGCTCC-
CACCC-39. PCR parameters were as follows: 94uC for 2 min,
followed by 40 cycles of 94uC for 15 s, 58.5uC for 30 s, and 68uC
for 4 min followed by a final extension of 68uC for 5 min. The
product of the first-round PCR was used as a template in the
second-round PCR under same conditions with the following PCR
parameters: 94uC for 2 min, followed by 45 cycles of 94uC for
15 s, 61uC for 30 s, and 68uC for 4 min followed by a final
extension of 68uC for 15 min. The resulting amplicons were then
inspected on a 1% agarose gel (Sigma-Aldrich, St. Louis, MO). All
PCR procedures were carried out under clean PCR conditions
with appropriate negative controls. A target of 20–30 single-
genome sequences were generated for each compartment at each
time point. This was followed by direct sequencing of the uncloned
amplicons.
DNA sequencing
HIV-1 env gene products were directly sequenced using an
automated ABI Prism 3730xl DNA analyzer. (Applied Biosystems,
Inc.). Both strands of DNA were sequenced with partially
overlapping fragments. All sequencing chromatograms were
carefully inspected for sites of ambiguous sequence (double peaks).
Sequences for which any chromatogram revealed double peaks
were excluded from further analysis, as this was indicative of
amplification from more than one template or early Taq
polymerase error.
Sequence alignments
Individual sequence fragments for each amplicon were
assembled using the CAP3 DNA sequence assembly program
[109]. Multiple alignments of nucleotide sequences were produced
using Clustal W [110] with the following parameters: pairwise
alignment gap opening penalty 10; gap extension penalty 0.1;
multiple alignment gap opening penalty 3; gap extension penalty
1.8. All resulting alignments were inspected and corrected
manually using the Alignment Explorer in the MEGA 4.0
software [78] when warranted. Columns with gaps were then
removed from the multiple alignments using GapStrip (www.hiv.
lanl.gov) [79].
Determination of coreceptor usage phenotype
In order to characterize co-receptor usage in our patients, V3
loop nucleotide sequences were extracted from multiply aligned
full-length HIV-1 env for each participant using coordinates 7110–
7216 on the HXB2 reference genome via the Gene cutter program
on the HIV Los Alamos website www.hiv.lanl.gov. Translated V3
loop sequences were scored using the SINSI position-specific
scoring matrix [PSSM] as per Jensen et al. [72].
Sequence diversity analysis and phylogenetic tree
construction
The ‘‘distance matrix’’ calculation in MEGA 4.0.2 [78] was
used to determine average pairwise genetic distances within or
between compartments. Pairwise distances among HIV-1 env
genes were determined using Tamura-Nei substitution model in
Mega 4.0.2. Sequences were analyzed for average within
compartment-and between compartment diversity. The Findmo-
del tool on the Los Alamos HIV database site http://www.hiv.
lanl.gov/was used to determine the most appropriate nucleotide
substitution model for data description. Overall, the phylogenetic
model found to best describe the data while allowing for distance
matrix calculations to be performed in MEGA 4.0.2 was the
Tamura-Nei model [111]. Phylogenetic trees were constructed by
the maximum likelihood (ML) method using the Tamura-Nei
evolutionary model in the PhyML program [112]. Bootstrap test
of phylogeny were performed on 1000 replicates to evaluate the
reliability and robustness of each internal branch in the resulting
phylogenies. Each set of sequences was then visually inspected
using the Highlighter tool available through the Los Alamos HIV
website (www.hiv.lanl.gov).
Bayesian Markov Chain Monte Carlo (MCMC) inference of
phylogeny was also performed at the nucleotide level using
MrBayes version 3.1.2 [85] with the Tamura-Nei nucleotide
substitution model of evolution. Neighbor-Joining phylogenies
were used as a starting point. Two simultaneous independent runs
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length 1610‘7 sampling every 100 generations. The analyses were
run until convergence, as determined by an average standard
deviation of split frequencies ,0.01. Discarding the first 25% as
burn-in, a majority-rule consensus of trees sampled from the
posterior distribution was used to derive node support.
Hypermutation analysis
Enrichment for mutations with APOBEC3G/F signatures was
assessed using Hypermut 2.0 (www.hiv.lanl.gov) [79]. For each
intra-patient set, the most common form in the first sampled time
point was used as the reference sequence. Sequences that yielded a
Fischer’s exact p-value of 0.05 or lower were considered
significantly hypermutated and excluded from analyses of
sequence diversity.
Recombination analyses
Recombinant sequence identification for IIA was performed
using Recco [88] and by visual inspection of Highlighter analysis
plots. One thousand permutations were run. The method of
Hudson and Kaplan [86] as employed in the DnaSP 5.10 software
package [87] was used to estimate the minimum number of
recombination events required to explain sequence datasets.
Sequences with evidence of recombination in Recco were
excluded from analyses of sequence diversity.
Compartmentalization analysis
A nonparameteric test for panmixia was used to calculate shifts
in population structure [90]. The online version of this test was
applied from the site at http://wwwabi.snv.jussieu.fr/,achaz/
hudsontest.html. The online portal allows for the input of intra-
patient SGA derived HIV-1 env multiple alignments from the
compartments (PBMC and GALT) and time points under
consideration. This test was derived from a geographic subdivision
detection test proposed by Hudson et al. [91] and compares an
estimate of the degree of genetic differentiation in subpopulations
of SGS chosen for comparison. In the absence of genetic
differentiation between subpopulations, random reassignment of
SGSs to different groups would be expected to recapitulate a new,
imaginary population with population structures with the same
distribution as the experimentally observed subpopulation. Ten
thousand (10,000) re-labelings/permutations were used to gener-
ate a p-value for the probability that the randomized SGS-derived
population structures between compartments are statistically
equivalent.
The Slatkin-Maddison test [93] as implemented in the HyPhy
software package [94], was also used to detect population structure
amongst HIV-1 env sequences within individual ML phylograms as
indicated. The significance of group separation was determined
using the permutation test (1000 permutations).
Nucleotide sequence accession numbers
All non-hypermutated HIV-1 env sequences discussed in this
manuscript have been deposited in GenBank (accession numbers
JQ250832-JQ251198).
Supporting Information
Figure S1 Bayesian inference (BI) phylogenetic trees
from all individuals. BI trees of SGA sequences from positive
control (A) POS1 (B) POS2 and experimental patients (C) HIA (D)
IIA (E) LIA. For all panels, PBMC time point #1 (open red circles)
and PBMC time point #2 (closed red circles) are shown. For
experimental individuals, GALT time point #1 (open blue
squares) and GALT time point #2 (closed blue squares) are also
shown. Posterior probabilities over 85% are indicated. The scale
bar represents 0.005 nucleotide substitutions per site. HXB2 was
used as an outgroup. Starred sequences represent those deter-
mined to be hypermutated. Sequences surrounded by boxes
represent HIV-1 env recombinants (red boxes denote a sequence p
value of p,0.05 in Recco; black boxes denote a sequence p value
of p,0.25 in Recco).
(TIF)
Table S1 Patient IIA – sequence recombination break-
points and levels of significance. Recombinant sequences
identified by manual interrogation of Highlighter plots and Recco
analysis for patient IIA are listed with recombination breakpoints
and corresponding sequence p-values. Sequence p-values were
derived from 1000 permutations. The method of Hudson and
Kaplan as employed in the DnaSP 5.10 software package was used
to estimate the minimum number of recombination events
required to explain sequence datasets.
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